Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMinia University
About this trial
To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes
Eligibility criteria
Qualifiers
Age ≥ 18 years. Histologically confirmed solid malignancy. Planned treatment with cisplatin starting from a dose of 60 mg/m2 per cycle (21-28 days each or fractionated).
Disqualifiers
Pre existing renal impairment (eGFR < 60〖" mL/min/1.73 m" 〗²or serum creatinine > 1.5 × upper limit of normal).
Trial design
Treatments tested in this trial
- Alpha-Lipoic Acid (ALA)
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Minia University
Lead sponsor
Minia University Hospital
Collaborator
Source ClinicalTrials.gov